First Ever

Kichler Lighting Elevates Outdoor Ambiance and Style with Latest Collections

Retrieved on: 
Friday, December 8, 2023
Glass, Lighting, Branner, Lowe's, Talman, Weather, Element, LED, First Ever, Hone, Creative, The Home Depot, Kroft, Environment, Interior design, Dimension stone, Woodworking, Régence, Camillo

SOLON, Ohio, Dec. 8, 2023 /PRNewswire/ -- Kichler Lighting LLC, a leader in innovative lighting and ceiling fans, redefines style and ambiance with every glowing detail of its Decorative Exterior Lighting collections. The latest release embraces luxe elements of both modern and updated traditional lifestyle trends – without compromising functionality and performance – to create the perfect outdoor oasis for any home.

Key Points: 
  • SOLON, Ohio, Dec. 8, 2023 /PRNewswire/ -- Kichler Lighting LLC , a leader in innovative lighting and ceiling fans, redefines style and ambiance with every glowing detail of its Decorative Exterior Lighting collections.
  • The Decorative Exterior Lighting collections include nine families, available in Textured Black or Olde Bronze finishes and varying sizes to fit every outdoor space:
    The Mathus collection updates the traditional lantern style for a new, luxe look.
  • With its soft pill shape, the Brix Outdoor Wall Light keeps the carriage lantern style trendy and timeless.
  • Kichler Lighting products are available at independent showrooms, Lowe's, Home Depot, electrical and landscape distributors, and online.

OXFORD PROPERTIES BREAKS GROUND ON 165,000 SQ FT EXPANSION OF IONIS PHARMACEUTICALS CARLSBAD CAMPUS

Retrieved on: 
Tuesday, December 5, 2023
Spinal muscular atrophy, Foot, Acquisition, Research, Scripps Research, Patient, Investment, Ecosystem, Science, ALS, First Ever, Therapy, Novartis, San Francisco Bay Area, Partnership, Oxford Properties, Growth, Ionis Pharmaceuticals, UC, San Diego State University, Thermo Fisher Scientific, RNA, Genentech, Grocery store, Fine chemical, Pharmaceutical industry, Ionis

Located in the San Diego life sciences submarket of Carlsbad, Ionis' existing campus features approximately 250,000 square feet of lab and office space.

Key Points: 
  • Located in the San Diego life sciences submarket of Carlsbad, Ionis' existing campus features approximately 250,000 square feet of lab and office space.
  • The expansion builds on Oxford and Ionis' established partnership, with Oxford completing a purchase and long-term lease back of Ionis' existing campus in October 2022.
  • Oxford entered the San Diego life sciences market in February 2022 via a US$464 million acquisition of a 13-building portfolio.
  • The campus expansion supports Ionis' strategic goals of prioritizing its wholly owned pipeline and advancing its drug discovery technology.

Densitas® Selects CancerIQ to Power Lifetime Risk, Patient Adherence as Part of its Industry Leading Mammography Quality AI Platform

Retrieved on: 
Sunday, November 26, 2023
Radiology, Navigation, Breast, RSNA, NCCN, Accreditation, Mammography Quality Standards Act, Breast cancer, Patient, Electronic health record, Algorithm, FDA, Intelligence, American College, EQUIP, Machine learning, First Ever, American College of Radiology, Deep learning, Buffer, Partnership, ACR, Education, Medical device, Nursing

"Our collaboration with CancerIQ reflects our commitment to furnishing care providers with best-in-class solutions for breast health," said Mo Abdolell, founder and CEO, Densitas.

Key Points: 
  • "Our collaboration with CancerIQ reflects our commitment to furnishing care providers with best-in-class solutions for breast health," said Mo Abdolell, founder and CEO, Densitas.
  • Densitas offers a robust AI-driven mammography quality assurance platform that comprises intelliMammo® and intelliMaven™.
  • This integrated platform provides mammography facilities and clinical care teams with a comprehensive and scalable solution that boosts operational efficiency, improves mammography quality, and increases clinical confidence.
  • Importantly, it ensures compliance with the FDA's Mammography Quality Standards Act (MQSA) EQUIP and the American College of Radiology's standards.

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

Retrieved on: 
Saturday, November 4, 2023
FDA, AMD, AAO, Geographic atrophy, First Ever, American Academy, GA, American Academy of Ophthalmology, Annual general meeting, Patient, GALE, APLS, Pharmaceutical industry

WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the first-ever FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data were reported during an oral presentation at the American Academy of Ophthalmology (AAO) Annual Meeting.

Key Points: 
  • “We are continuing to see increasing SYFOVRE treatment effects year-over-year and a more than 40% reduction in nonsubfoveal lesion growth in the third year,” said Caroline Baumal, M.D., chief medical officer, Apellis.
  • “Additionally, SYFOVRE is the only treatment that offers dosing beyond 12 months, and these results demonstrate the importance of early and continuous treatment over time.”
    SYFOVRE continued to demonstrate increasing treatment effects over time.
  • Reduced nonsubfoveal GA lesion growth with both monthly (42%; p
  • Approximately 92% of patients enrolled in GALE completed the first year of the study, demonstrating robust long-term treatment compliance.

Joshua S. Bauchner Joins Mandelbaum Barrett PC as Chair of its Cannabis & Psychedelics Practice Group and Partner in its Litigation Practice Group

Retrieved on: 
Thursday, October 5, 2023
District court, Bankruptcy, Howard Bauchner, Consumer protection, Brooklyn Law School, Strategic planning, United States Coast Guard Legal Division, Ground substance, Partner, Manhattan, Community association, Fortune 500, DOJ, Cannabis, Psilocybin, Environment, Ernst & Young Entrepreneur of the Year Award, United States Court of Appeals for the Third Circuit, First Ever, Committee, Trustee, United States Court of Appeals for the Second Circuit, Second, Manhattan Community Board 10, Philippine House Special Committee on Land Use, Sale, Wheaton College, Drug, Property management

ROSELAND, N.J., Oct. 5, 2023 /PRNewswire-PRWeb/ -- Joshua S. Bauchner joined Mandelbaum Barrett PC as Chair of its expanded Cannabis & Psychedelics Practice Group and a Partner in its Litigation Practice Group. The firm also announced that it has renamed its Cannabis Practice as the Cannabis & Psychedelics Practice Group to reflect this growing, multifaceted and complex area of law that includes cannabis and psychedelics.

Key Points: 
  • ROSELAND, N.J., Oct. 5, 2023 /PRNewswire-PRWeb/ -- Joshua S. Bauchner joined Mandelbaum Barrett PC as Chair of its expanded Cannabis & Psychedelics Practice Group and a Partner in its Litigation Practice Group .
  • The firm also announced that it has renamed its Cannabis Practice as the Cannabis & Psychedelics Practice Group to reflect this growing, multifaceted and complex area of law that includes cannabis and psychedelics.
  • He will be based in the firm's Roseland, NJ, office and also will maintain an office in its New York City offices.
  • Bauchner represents a diverse client base from start- ups to Fortune 500 companies, as well as cannabis operators and applicants.

High-End Performance Meets Style and Comfort in Kichler Lighting's New Ceiling Fans Décor Release

Retrieved on: 
Tuesday, October 3, 2023
Lighting, Nickel, The Home Depot, Ceiling, Light, CCT, ABS, LED, Collection, Nani, UV, Lowe's, Relaxation, Environment, Breda, First Ever, Heating, ventilation, and air conditioning, Cosmetics

SOLON, Ohio, Oct. 3, 2023 /PRNewswire/ -- Kichler Lighting LLC, a leader in innovative lighting and ceiling fans, gives any space a breath of fresh air with its new Ceiling Fans Décor. This introduction of four new families is engineered for performance and comfort while boasting sophisticated, on-trend designs.

Key Points: 
  • SOLON, Ohio, Oct. 3, 2023 /PRNewswire/ -- Kichler Lighting LLC , a leader in innovative lighting and ceiling fans, gives any space a breath of fresh air with its new Ceiling Fans Décor.
  • This introduction of four new families is engineered for performance and comfort while boasting sophisticated, on-trend designs.
  • "Our latest Ceiling Fans Décor release bridges the gap between the delivery of cooling comfort and elevated design," says Kichler Lighting's Product Manager, Ceiling Fans, Scott Williams.
  • Whether that be luxe, modern, or global, these fans are designed to meet you where you are and take your space to the next level."

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

Retrieved on: 
Tuesday, October 3, 2023
ACT, Bleeding, RRT, Clinical trial, Research, Trial of the century, Dialysis, Daubert v. Merrell Dow Pharmaceuticals, Inc., PMA, Publishing, Patient, Agency, Risk, Renal replacement therapy, IDE, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Heparin, First Ever, Food, Safety, Medical imaging, Pharmaceutical industry

SAN MATEO, Calif., Oct. 3, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it is advancing Niyad™ (a lyophilized formulation of nafamostat) into a registrational study following the recent approval of an Investigational Device Exemption (IDE) submission to the United States Food and Drug Administration (FDA).  This clinical trial will evaluate the safety and efficacy of Niyad to support a premarket approval application (PMA) expected to be submitted in the second half of 2024. The single study will consist of 166 adult patients undergoing renal replacement therapy (RRT) who cannot tolerate heparin or are at risk for bleeding.  If approved, Niyad would be the first-ever FDA-approved regional anticoagulant for the extracorporeal circuit in the U.S.

Key Points: 
  • This clinical trial will evaluate the safety and efficacy of Niyad to support a premarket approval application (PMA) expected to be submitted in the second half of 2024.
  • The single study will consist of 166 adult patients undergoing renal replacement therapy (RRT) who cannot tolerate heparin or are at risk for bleeding.
  • The primary endpoint of the study is mean post-filter activated clotting time (ACT) over the first 24 hours versus placebo.
  • Based on the feedback from the  Emergency Use Authorization request, the FDA stated that AcelRx should proceed with the clinical study.

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

Retrieved on: 
Wednesday, September 27, 2023
Biotechnology, General Health, Pharmaceutical, Health, New Drug Application, Novin, United States bankruptcy court, Bayer, Molluscum contagiosum, PDUFA, First Ever, Bankruptcy, Cryptocurrency, Ligand

On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to provide up to $15 million in debtor-in-possession (“DIP”) financing.

Key Points: 
  • On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to provide up to $15 million in debtor-in-possession (“DIP”) financing.
  • In September 2023, the Bankruptcy Court approved a $12.2 million bid from Ligand to purchase berdazimer gel and all the assets related to the NITRICIL™ technology platform, and the rights to the Bayer-partnered Sitavig program.
  • The approved $12.2 million bid was credited to the $15 million DIP financing, with the balance of $2.8 million and accrued interest repaid to Ligand.
  • “We are pleased with the outcome of the bankruptcy proceeding resulting in Ligand’s full ownership of berdazimer gel, NITRICIL platform and related assets.

AvaSure Recognized as Leader in KLAS Virtual Sitting & Nursing Report for Driving ROI and Improving Patient & Staff Outcomes

Retrieved on: 
Thursday, September 21, 2023
Aggression, Research, Falls, KLAS, Investment, Patient, Nursing, Observation, AI, ROI, First Ever, Online shopping

BELMONT, Mich., Sept. 21, 2023 /PRNewswire/ -- A new Segment Insights report from KLAS revealed that AvaSure customers have recognized the virtual care platform's ability to improve staff and patient outcomes while driving better financial performance and significant return on investment.

Key Points: 
  • The report, the first-ever by KLAS on virtual sitting and virtual nursing solutions, is based on structured interviews of vendors' customers.
  • The KLAS report also found that customers have experienced positive financial outcomes from being able to scale sitters' capacity to observe patients and prevent adverse events.
  • Additionally, the 2022 KLAS Emerging Solutions Top 20 Report ranked AvaSure first for the greatest impact on reducing the cost of care.
  • Separately, the report revealed that respondents overwhelmingly agree that virtual sitting and nursing solutions have been helpful in addressing staffing shortages.

Eluvio Receives Industry "Best of Show" Award at IBC 2023 for its Media Wallet

Retrieved on: 
Thursday, September 21, 2023
Smart TV, Fox Entertainment Group, AirPlay, IBC, International, Apple TV, FAST, Amazon Fire TV, PVOD, Flash, API, Connected, Microsoft, Textile, Metro-Goldwyn-Mayer, Economics, Globo, Warner Bros., Internet, Flash (DC Comics character), Android TV, Fire, TV Technology, HTTP, Golden Key International Honour Society, WWE, Wallet, Sony Pictures, DRM, First Ever, Video game, Mobile phone, Telstra

BERKELEY, Calif., Sept. 20, 2023 /PRNewswire/ -- Content Fabric pioneer, Eluvio, received the esteemed TV Technology "Best of Show" Award at the 2023 IBC Show for the Eluvio Media Wallet for Connected TV, powered by the Eluvio Content Fabric. The awards were judged by a panel of industry experts on the criteria of innovation, feature set, cost efficiency and performance in serving the media and entertainment industry.

Key Points: 
  • - The Eluvio Media Wallet is a universal personal media vault for all major Connected TV platforms that expands the reach of the Content Fabric – an open and decentralized streaming, content distribution and storage network – to mainstream consumers at scale
    BERKELEY, Calif., Sept. 20, 2023 /PRNewswire/ -- Content Fabric pioneer, Eluvio , received the esteemed TV Technology " Best of Show " Award at the 2023 IBC Show for the Eluvio Media Wallet for Connected TV, powered by the Eluvio Content Fabric .
  • The Content Fabric is an open and decentralized, streaming, content distribution, and storage network built for the third generation Internet.
  • Similarly, the Eluvio Media Wallet allows publishers to offer content under any sell through model and window (ownership, subscription pass, or ad supported).
  • "We are honored to be recognized with this 'Best of Show' Award from TV Technology at IBC 2023," said Michelle Munson, CEO and co-founder of Eluvio.